Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the US to Spur Market GrowthGBI Research
July 10, 2012
141 Pages - SKU: XGBR3958732
Additional InformationOnly FDA Approval Pathway Complications are Holding Back the US Biosimilars Flood.
New guidelines laid out by the US Food and Drug Administration (FDA) lack clarity and specificity, meaning that a wealth of biosimilars are currently restricted from the world’s biggest pharmaceutical market, states a new report from healthcare industry analysts GBI Research.
The report* says that ambiguity within the healthcare authority’s approval pathway procedure suggests decisions will be made on a case-by-case basis, hindering the flow of biosimilars into the US market.
As biosimilars require high investments and long periods of development compared to generics, companies need to know in advance what US regulators will require when they submit their applications for the approval of a new product.
GBI Research expects the first biosimilar to be approved in the US by the end of this year, followed by products by Sandoz and Hospira in early 2013. Once these medications have broken through, and a clearer approval pathway is established, an abundance of biosimilars is expected to follow and take advantage of the highly lucrative US pharmaceutical market.
Europe has already approved 14 biosimilars – the highest of any region – with a range of products belonging to the erythropoietin (EPO) and granulocyte colony stimulating factors (G-CSF) and human growth hormones (HGH) groups. Japan launched its first biosimilar in October 2009.
The reduction of healthcare expenditure is at the top of the agenda for national healthcare authorities around the globe, and as biologics are among the highest priced therapies in the world, establishing governing regulations is a key focus.
GBI Research predicts that the value of the worldwide biologics market will rocket from $450m in 2011 to $7.5 billion in 2018, climbing at a highly impressive Compound Annual Growth Rate (CAGR) of 49.6%. This staggering jump is attributed to the entrance of the US into the global biologics market.
* Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the US to Spur Market Growth
This report provides key data, information and analysis of the major trends and issues affecting the biosimilar market in developed countries covering the US, the top five European markets and Japan
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
More Biosimilars reports by GBI Research
Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion by GBI Research
Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales ErosionSummaryGBI Research, the ...
Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities by GBI Research
Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth OpportunitiesSummaryGBI Research, the leading business intelligence provider, ...
Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region by GBI Research
Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key ...
Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value Offerings by GBI ResearchSee all reports like this >>
Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value OfferingsSummaryGBI Research, the leading business intelligence provider, ...
More Europe Biosimilars reports
Italy Pharmaceutical Market Overview – Challenging outlook due to austerity and falling birth rate by Datamonitor
IntroductionHigh national debt and a falling birth rate create a poor economic outlook and challenging market environment for pharma companies in Italy. Generic penetration is ...
EU Biosimilars Database by Datamonitor
IntroductionDetails of all marketed and pipeline biosimilars in the EU. View by product, selecting a molecule name; assess a biosimilar company's pipeline; or view the ...
Analysis of European Biosimilars Market by Frost & Sullivan
The aim of this research study is to thoroughly assess and analyse the biosimilars market, as well as market and technology trends in Europe, in ...
The Pharmaceutical Market: Portugal by Espicom Healthcare IntelligenceSee all reports like this >>
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting ...
More Europe reports
European SMB Market Watch Update: January–March 2013 by IDC
This IDC Update presents coverage of the European SMB sector in the first quarter of 2013, with a focus on new products and services, initiatives, ...
Painters & Decorators - Scotland (UK) - Industry Report by Plimsoll Publishing Ltd.
Plimsoll Publishing’s UK Painters & Decorators - Scotland Analysis provides a detailed overview of the UK Painters & Decorators - Scotland market and delivers a ...
Tampons Market in Czech Republic to 2016 by Canadean Ltd
SynopsisThe report presents detailed data on consumption trends in the Tampons category in Czech Republic, analyzing consumption volumes and values. It also provides indispensable data ...
D&B Country Report: Portugal by Dun & Bradstreet Inc.See all reports like this >>
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
We can help you find what you need. Call us or write us:
Need help in your search?
- Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors
- Russia Generics and Biosimilars
- Italy Pharmaceutical Market Overview – Challenging outlook due to austerity and falling birth rate
- Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies
- Global Biosimilars Market - Products, Applications and Regulations